Small cell lung cancer · line 1 · Durvalumab consolidation post-CRT (LS-SCLC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-DURVA-CONSOLIDATION-SCLC |
| ID | IND-SCLC-LS-CONSOLIDATION-DURVA |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-08 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-SCLC |
| Sources | SRC-ADRIATIC-CHENG-2024 SRC-ESMO-SCLC-2021 SRC-NCCN-SCLC-2025 |
Notes
Sequential after IND-SCLC-LIMITED-1L (concurrent CRT). Reflects post-2024 standard-of-care shift; SRC-ESMO-SCLC-2021 predates ADRIATIC and may not yet reflect this consolidation strategy — flagged for currency review when ESMO refreshes SCLC guideline. Durva+tremelimumab arm in ADRIATIC did NOT improve outcomes over durva alone — only the monotherapy arm is the approved regimen.
Used By
Algorithms
ALGO-SCLC-1L- ALGO-SCLC-1L